Elevated Plasma Matrix Metalloproteinase 8 Associates With Sputum Culture Positivity in Pulmonary Tuberculosis.
HIV
Tuberculosis
diagnosis
immunopathology
matrix metalloproteinase
procollagen III N-terminal propeptide
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
13 09 2022
13 09 2022
Historique:
received:
10
12
2021
accepted:
28
04
2022
pubmed:
6
5
2022
medline:
16
9
2022
entrez:
5
5
2022
Statut:
ppublish
Résumé
Current methods for tuberculosis treatment monitoring are suboptimal. We evaluated plasma matrix metalloproteinase (MMP) and procollagen III N-terminal propeptide concentrations before and during tuberculosis treatment as biomarkers. Plasma MMP-1, MMP-8, and MMP-10 concentrations significantly decreased during treatment. Plasma MMP-8 was increased in sputum Mycobacterium tuberculosis culture-positive relative to culture-negative participants, before (median, 4993 pg/mL [interquartile range, 2542-9188] vs 698 [218-4060] pg/mL, respectively; P = .004) and after (3650 [1214-3888] vs 720 [551-1321] pg/mL; P = .008) 6 months of tuberculosis treatment. Consequently, plasma MMP-8 is a potential biomarker to enhance tuberculosis treatment monitoring and screen for possible culture positivity.
Identifiants
pubmed: 35510939
pii: 6576469
doi: 10.1093/infdis/jiac160
pmc: PMC9470104
mid: EMS146265
doi:
Substances chimiques
Biomarkers
0
Matrix Metalloproteinase 8
EC 3.4.24.34
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
928-932Subventions
Organisme : Wellcome Trust
ID : 210662
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/P023754/1
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : K08 AI106420
Pays : United States
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Déclaration de conflit d'intérêts
Potential conflicts of interest . All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.
Références
EBioMedicine. 2017 Nov;25:112-121
pubmed: 29100778
J Clin Invest. 2011 May;121(5):1827-33
pubmed: 21519144
J Infect Dis. 2013 Nov 15;208(10):1571-9
pubmed: 23922364
PLoS One. 2013 Apr 22;8(4):e61333
pubmed: 23613834
Medicine (Baltimore). 2015 Sep;94(39):e1628
pubmed: 26426648
Clin Infect Dis. 2017 Jul 1;65(1):121-132
pubmed: 28475709
Am J Respir Crit Care Med. 2012 May 1;185(9):989-97
pubmed: 22345579
PLoS Pathog. 2015 May 21;11(5):e1004917
pubmed: 25996154
Nat Rev Immunol. 2013 Sep;13(9):649-65
pubmed: 23969736
Lancet Respir Med. 2013 Aug;1(6):462-70
pubmed: 24429244
J Infect Dis. 2015 Aug 1;212(3):463-73
pubmed: 25676469
Int J Mol Sci. 2019 Mar 18;20(6):
pubmed: 30889803